menu
    • menu
    [{"orgOrder":0,"company":"Intech Biopharm Ltd","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Microorganism","year":"2021","type":"Private Placement","leadProduct":"Decoy20","moa":"||Toll-like-4 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Intech Biopharm Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intech Biopharm Ltd \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Intech Biopharm Ltd \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Acepodia","sponsor":"Digital Mobile Venture","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2021","type":"Series C Financing","leadProduct":"ACE1831","moa":"CD20","graph1":"Oncology","graph2":"Preclinical","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acepodia \/ Digital Mobile Venture","highestDevelopmentStatusID":"4","companyTruncated":"Acepodia \/ Digital Mobile Venture"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"DotBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"DB007","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bora Pharmaceuticals \/ DotBio","highestDevelopmentStatusID":"4","companyTruncated":"Bora Pharmaceuticals \/ DotBio"},{"orgOrder":0,"company":"Mycenax Biotech","sponsor":"Hummingbird Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"HMBD-002","moa":"VISTA","graph1":"Oncology","graph2":"Preclinical","graph3":"Mycenax Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mycenax Biotech \/ Hummingbird Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Mycenax Biotech \/ Hummingbird Bioscience"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Almac Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"ALM-401","moa":"EGFR\/ROR1","graph1":"Oncology","graph2":"Preclinical","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Formosa Pharmaceuticals \/ Almac Group","highestDevelopmentStatusID":"4","companyTruncated":"Formosa Pharmaceuticals \/ Almac Group"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Formosa Pharmaceuticals

                            Taiwan arrow
                            Pharmex
                            Not Confirmed

                            Formosa Pharmaceuticals

                            Taiwan arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALM-401

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Almac Group

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Formosa and Almac Ink License Deal for ALM-401 Bispecific ADC for Tumors

                            Details : The agreement aims for exclusive rights to the commercialization of ALM-401, a first-in-class, bispecific ADC for the treatment of solid tumors characterized by the dual expression of EGFR and ROR1.

                            Product Name : ALM-401

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            May 06, 2025

                            Lead Product(s) : ALM-401

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Almac Group

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bora Pharmaceuticals

                            Taiwan arrow
                            Pharmex
                            Not Confirmed

                            Bora Pharmaceuticals

                            Taiwan arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DB007

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : DotBio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Bora Biologics, DotBio Enter Strategic CMC Development Collaboration

                            Details : The collaboration aims to advance the development of DotBio’s Tri-Specific Antibody DB007 for the treatment of Cancer.

                            Product Name : DB007

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            January 09, 2025

                            Lead Product(s) : DB007

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : DotBio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Senhwa Biosciences

                            Taiwan arrow
                            Pharmex
                            Not Confirmed

                            Senhwa Biosciences

                            Taiwan arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pidnarulex

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Senhwa Submits IND for Pidnarulex Study in Advanced Solid Tumors Sponsored by NCI

                            Details : (CX-5461 (pidnarulex), is a first-in-class small-molecule designed to stabilize G-quadruplex structures, which is being evaluated for the treatment of Solid Tumors.

                            Product Name : CX-5461

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 17, 2024

                            Lead Product(s) : Pidnarulex

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Intech Biopharm Ltd

                            Taiwan arrow
                            Pharmex
                            Not Confirmed

                            Intech Biopharm Ltd

                            Taiwan arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Decoy20,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $30.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Intec Announces $30 Million Private Placement Ahead of Decoy Merger

                            Details : Decoy20 is single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma.

                            Product Name : Decoy20

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            July 26, 2021

                            Lead Product(s) : Decoy20,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $30.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Acepodia

                            Taiwan arrow
                            Pharmex
                            Not Confirmed

                            Acepodia

                            Taiwan arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ACE1831

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Digital Mobile Venture

                            Deal Size : $109.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Acepodia Raises $109 Million Series C Financing to Advance Development of First-in-Class Antibody Cell Effecto...

                            Details : The funds will be used to further validate the company’s ACC technology and advance its pipeline of antibody cell effector (ACE) therapies including ACE1831, for patients with cancer with limited treatment options.

                            Product Name : ACE1831

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 12, 2021

                            Lead Product(s) : ACE1831

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Digital Mobile Venture

                            Deal Size : $109.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Mycenax Biotech

                            Taiwan arrow
                            Pharmex
                            Not Confirmed

                            Mycenax Biotech

                            Taiwan arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HMBD-002

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Hummingbird Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Hummingbird Bioscience Announces Agreement with Mycenax Biotech for Production of Anti-VISTA Antibody

                            Details : Pre-clinical studies have shown that HMBD-002 can strongly inhibit tumor growth, both as a monotherapy and even more potently when combined with anti-PD(L)1 treatment.

                            Product Name : HMBD-002

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            February 20, 2020

                            Lead Product(s) : HMBD-002

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Hummingbird Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth